The present invention generally relates to compositions comprising and methods for forming functionalized carbon-based nanostructures.

A process for the preparation of a metal-organic compound, said metal-organic compound comprising at least one metal ion and at least one organic ligand, wherein said organic ligand is capable of associating with said metal ion, comprising at least the steps of; providing a first reactant comprising at least one metal in ionic form; providing a second reactant comprising at least one organic ligand capable of associating with said metal in ionic form; and admixing said first and second reactants under conditions of prolonged and sustained pressure and shear sufficient to synthesize said metal-organic compound.

A process for the preparation of a metal-organic compound, said metal-organic compound comprising at least one metal ion and at least one organic ligand, wherein said organic ligand is capable of associating with said metal ion, comprising at least the steps of; providing a first reactant comprising at least one metal in ionic form; providing a second reactant comprising at least one organic ligand capable of associating with said metal in ionic form; and admixing said first and second reactants under conditions of prolonged and sustained pressure and shear sufficient to synthesize said metal-organic compound.

The present invention relates to compounds of the formula I or II: (I) (II) processes for their preparation and their use as pharmaceutical agents or compositions in the treatment, of neurological disorders.

##STR00001##

The present invention relates to compounds of the formula I or II: (I) (II) processes for their preparation and their use as pharmaceutical agents or compositions in the treatment, of neurological disorders.

##STR00001##

A composition, consisting essentially of copper, a fluoroalkyl group, and a ligand comprising at least one group-V donor. The molar ratio of copper to the fluoroalkyl group is approximately 1.

A composition, consisting essentially of copper, a fluoroalkyl group, and a ligand comprising at least one group-V donor. The molar ratio of copper to the fluoroalkyl group is approximately 1.

The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.

The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.

A compound comprising a first ligand L.sub.A of Formula I,

##STR00001##

is disclosed. In the structure of Formula I, ring A is a 5-membered or 6-membered carbocyclic or heterocyclic ring; Z.sup.1-Z.sup.4 are each independently C or N; at least two consecutive Z.sup.1-Z.sup.4 are C, and are fused to a structure of Formula II

##STR00002##

or Formula III

##STR00003##

Y.sup.1; Y.sup.1 and Y.sup.2 are each independently O, S, Se, CRR′, SiRR′, or GeRR′; each R.sup.A, R.sup.B, R.sup.C, R, and R′ is a hydrogen or a substituent; and any two substituents may be joined or fused together to form a ring. In the compound, L.sub.A is complexed to a metal M by the dashed lines in Formula I to form a five-membered chelate ring, and M has an atomic weight greater than 40. Organic light emitting devices and consumer products containing the compounds are also disclosed.